{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:15:20Z","timestamp":1761920120799},"reference-count":24,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T00:00:00Z","timestamp":1457395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T00:00:00Z","timestamp":1457395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neurol Scand"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1111\/ane.12573","type":"journal-article","created":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T09:20:39Z","timestamp":1457428839000},"page":"129-133","source":"Crossref","is-referenced-by-count":14,"title":["Early safety and efficacy of fingolimod treatment in Denmark"],"prefix":"10.1155","volume":"135","author":[{"given":"A.","family":"Voldsgaard","sequence":"first","affiliation":[{"name":"Danish Multiple Sclerosis Center; Department of Neurology; Copenhagen University Hospital; Rigshospitalet; Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Koch-Henriksen","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology; University of Aarhus; Copenhagen Denmark"},{"name":"Danish Multiple Sclerosis Registry; Copenhagen University Hospital; Rigshospitalet; Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Magyari","sequence":"additional","affiliation":[{"name":"Danish Multiple Sclerosis Center; Department of Neurology; Copenhagen University Hospital; Rigshospitalet; Copenhagen Denmark"},{"name":"Danish Multiple Sclerosis Registry; Copenhagen University Hospital; Rigshospitalet; Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Sellebjerg","sequence":"additional","affiliation":[{"name":"Danish Multiple Sclerosis Center; Department of Neurology; Copenhagen University Hospital; Rigshospitalet; Copenhagen Denmark"},{"name":"University of Copenhagen; Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. S.","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"Danish Multiple Sclerosis Center; Department of Neurology; Copenhagen University Hospital; Rigshospitalet; Copenhagen Denmark"},{"name":"University of Copenhagen; Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. B.","family":"Oturai","sequence":"additional","affiliation":[{"name":"Danish Multiple Sclerosis Center; Department of Neurology; Copenhagen University Hospital; Rigshospitalet; Copenhagen Denmark"},{"name":"University of Copenhagen; Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2016,3,8]]},"reference":[{"key":"10.1111\/ane.12573-BIB0001|ane12573-cit-0001","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1345\/aph.1G424","article-title":"Fingolimod: a novel immunosuppressant for multiple sclerosis","volume":"41","author":"Brown","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1111\/ane.12573-BIB0002|ane12573-cit-0002","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"Oral fingolimod (FTY720) for relapsing multiple sclerosis","volume":"355","author":"Kappos","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12573-BIB0003|ane12573-cit-0003","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12573-BIB0004|ane12573-cit-0004","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/ane.12573-BIB0005|ane12573-cit-0005","unstructured":"Novartis Pharmaceuticals Corporation US prescribing information: Gilenya_(fingolimod) capsules http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/gilenya.pdfduct"},{"key":"10.1111\/ane.12573-BIB0006|ane12573-cit-0006","unstructured":"FDA Drug Safety Communication: Safety review of a reported death after the first dose of Multiple Sclerosis drug Gilenya (fingolimod)"},{"key":"10.1111\/ane.12573-BIB0007|ane12573-cit-0007","unstructured":"European Medicines Agency starts review of Gilenya (fingolimod)"},{"key":"10.1111\/ane.12573-BIB0008|ane12573-cit-0008","unstructured":"FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod)"},{"key":"10.1111\/ane.12573-BIB0009|ane12573-cit-0009","unstructured":"European Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya"},{"key":"10.1111\/ane.12573-BIB0010|ane12573-cit-0010","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1111\/ane.12573-BIB0011|ane12573-cit-0011","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ophtha.2012.12.040","article-title":"Ophtalmic evaluations in Clinical studies of fingolimod in Multiple Sclerosis","volume":"120","author":"Zarbin","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1111\/ane.12573-BIB0012|ane12573-cit-0012","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1212\/01.wnl.0000338569.32367.3d","article-title":"Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study","volume":"72","author":"O'Connor","year":"2009","journal-title":"Neurology"},{"key":"10.1111\/ane.12573-BIB0013|ane12573-cit-0013","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1352458509357065","article-title":"Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results","volume":"16","author":"Comi","year":"2010","journal-title":"Mult Scler"},{"key":"10.1111\/ane.12573-BIB0014|ane12573-cit-0014","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/1352458513513059","article-title":"Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis","volume":"20","author":"Izquierdo","year":"2014","journal-title":"Mult Scler"},{"key":"10.1111\/ane.12573-BIB0015|ane12573-cit-0015","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(11)70099-0","article-title":"Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomized extension of the TRANSFORMS study","volume":"10","author":"Khatri","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1111\/ane.12573-BIB0016|ane12573-cit-0016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1471-2377-14-65","article-title":"Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial","volume":"1","author":"Laroni","year":"2014","journal-title":"BMC Neurol"},{"key":"10.1111\/ane.12573-BIB0017|ane12573-cit-0017","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00415-013-7115-8","article-title":"Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study","volume":"261","author":"Gold","year":"2014","journal-title":"J Neurol"},{"key":"10.1111\/ane.12573-BIB0018|ane12573-cit-0018","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00228-011-1146-9","article-title":"Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers","volume":"68","author":"Schmouder","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/ane.12573-BIB0019|ane12573-cit-0019","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1111\/ane.12082","article-title":"Switching from natalizumab to fingolimod: an observational study","volume":"128","author":"Sempere","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/ane.12573-BIB0020|ane12573-cit-0020","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1007\/s00415-013-7082-0","article-title":"Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort","volume":"260","author":"Braune","year":"2013","journal-title":"J Neurol"},{"key":"10.1111\/ane.12573-BIB0021|ane12573-cit-0021","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jns.2012.09.009","article-title":"Early tolerability and safety of fingolimod in clinical practice","volume":"323","author":"Ontaneda","year":"2012","journal-title":"J Neurol Sci"},{"key":"10.1111\/ane.12573-BIB0022|ane12573-cit-0022","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3109\/00207454.2014.969839","article-title":"Experience with fingolimod in clinical practice","volume":"125","author":"Hersh","year":"2015","journal-title":"Int J Neurosci"},{"key":"10.1111\/ane.12573-BIB0023|ane12573-cit-0023","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/1352458512447596","article-title":"Prolonged and symptomatic bradycardia following a single dose of fingolimod","volume":"19","author":"Faber","year":"2013","journal-title":"Mult Scler"},{"key":"10.1111\/ane.12573-BIB0024|ane12573-cit-0024","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.0000000000000137","article-title":"Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis","volume":"82","author":"Karlsson","year":"2014","journal-title":"Neurology"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12573","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fane.12573","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ane.12573\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:49:29Z","timestamp":1671540569000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ane.12573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,8]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"URL":"https:\/\/doi.org\/10.1111\/ane.12573","archive":["Portico"],"relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3,8]]}}}